Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
AVROBIO’s Merger with Tectonic Therapeutic
Myrobalan Therapeutics’ $24 Million Series A Funding Round
Goodwin represented Myrobalan Therapeutics on the matter. Myrobalan Therapeutics announced its $24 million Series A financing. The round was led by Co-win Ventures, with participation from...
Merck’s $680 Million Acquisition of Harpoon Therapeutics
Evercore Group L.L.C. acted as financial advisor to Merck in this transaction and Covington & Burling LLP acted as its legal advisor. Centerview Partners LLC acted...
SpringWorks Therapeutics’ $316.25 Million Underwritten Common Stock Offering
Goodwin advised SpringWorks Therapeutics, Inc. on the offering. American precision medicine company SpringWorks Therapeutics (Nasdaq: SWTX) has closed a public offering of 10,905,171 shares of its common...
Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Rapport Therapeutics’ $150 Million Series B Funding Round
Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
BlueRock Therapeutics and bit.bio’s Collaboration and Option Agreement
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
CathWorks’ Acquisition Option Agreement and Co-promotion Agreement with Medtronic
Goodwin Procter advised CathWorks on the deal. CathWorks announced its acquisition option agreement and co-promotion agreement with Medtronic (NYSE: MDT). Under the acquisition option agreement, Medtronic will...
Sichuan Kelun-Biotech Biopharmaceutical’s License Agreement with Merck
Goodwin Procter advised Sichuan Kelun-Biotech Biopharmaceutical Co. on the deal. Sichuan Kelun-Biotech Biopharmaceutical Co. announced its exclusive license and collaboration agreement with Merck for ex-China development...
PepGen’s $108 Million Initial Public Offering
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...